What's new in genitourinary pathology 2023: WHO 5th edition updates for urinary tract, prostate, testis, and penis. [PDF]
Choy B, Tretiakova M, Zynger DL.
europepmc +1 more source
Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer. [PDF]
Kaushal JB +3 more
europepmc +1 more source
Diagnostic value of CD138 and GATA3 in benign prostatic hyperplasia and prostate cancer. [PDF]
Hu Y +5 more
europepmc +1 more source
Editorial - Why do we keep reporting high-grade prostatic intraepithelial neoplasia (HGPIN)?
openaire +1 more source
Lesion volume on multiparametric magnetic resonance imaging as a non-invasive prognosticator for clinically significant prostate cancer. [PDF]
Choudhary MK +6 more
europepmc +1 more source
Lesion size may affect diagnostic capabilities of MRI-guided ultrasound fusion biopsy and cognitive targeted biopsy for clinically significant prostate cancer. [PDF]
Shao IH +11 more
europepmc +1 more source
Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate. [PDF]
Ertunc O +10 more
europepmc +1 more source
Related searches:
AbstractPURPOSEHigh‐grade prostatic intraepithelial neoplasia (HGPIN) is believed to be a precursor of prostate cancer (PCa). This study evaluated whether HGPIN was located close to PCa in whole radical prostatectomy specimens (RPSs).MATERIALS AND METHODSWe evaluated 1,374 prostate specimens from 1999 to 2010 using a cMDX‐based map model of the ...
Okyaz, Eminaga +6 more
openaire +2 more sources
Apolipoprotein‐D: A novel cellular marker for HGPIN and prostate cancer
The Prostate, 2003AbstractBACKGROUNDHigh grade prostatic intraepithelial neoplasia (HGPIN) is a putative pre‐malignant lesion of the prostate. While apolipoprotein‐D (Apo‐D), an androgen‐regulated hydrophobic transporter protein, is expressed in prostate tumors, its expression in HGPIN is unknown.METHODSImmunoreactivity for Apo‐D and another androgen‐regulated protein ...
Neufing, Petra +8 more
openaire +3 more sources

